Israeli cell therapy biotech Pluristem Therapeutics has secured up to €50M in non-dilutive funding from the European Investment Bank to progress its coronavirus-targeting cell therapy to phase III.

The partners plan to sign the funding agreement at the end of April and Pluristem will initially receive €20M followed by two further installments totaling up to €30M. Source: Labiotech 29/4/2020